Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by 2019champson Nov 16, 2021 5:33pm
197 Views
Post# 34133938

Almost at $4 before news

Almost at $4 before newsCouple of months ago i thought $2 before news would be a good spot to be in. Fast forward, we are at $4 before news. I just can't see a company taking this long to come out and say the data wasn't good or inconclusive. It just doesn't make sense. No raise at an all time high either? Folks, this is big. If data wasn't good you would do a raise like AGN or APLI did ASAP. Not the case here. That has me thinking either A) Company has stellar data and thinks they can raise much higher or B) the funding is coming from elsewhere for a potential phase 3. The savy investors know this and are buying. The clueless folks who think the delay is bad news are selling lol, and then you still have delusional canadian investors who think aurora cannabis is a great investment. We are in terrific shape here folks.
<< Previous
Bullboard Posts
Next >>